Actively Recruiting
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Led by Ruijin Hospital · Updated on 2025-02-19
400
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell lymphoma
CONDITIONS
Official Title
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female
- No prior treatment for DLBCL, including chemotherapy, targeted therapy, or immunotherapy
- Confirmed diffuse large B-cell lymphoma with double expression of MYC and BCL2 by pathology, or presence of TP53 or other epigenetic gene mutations, or MYC and BCL2 double hit
- Plan to receive or currently receiving a treatment regimen containing tucidinostat
- Voluntarily sign informed consent
You will not qualify if you...
- Currently enrolled or planning to participate in any interventional clinical trial
- Expected survival time less than 6 months
- Any other reason deemed unsuitable by the investigators for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
P
Pengpeng Xu, professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here